Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate
Durability Test Remains
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
